key: cord-0025551-lrdyzvxe
authors: Jukič, Marko; Kores, Katarina; Janežič, Dušanka; Bren, Urban
title: Repurposing of Drugs for SARS-CoV-2 Using Inverse Docking Fingerprints
date: 2021-12-28
journal: Front Chem
DOI: 10.3389/fchem.2021.757826
sha: 0acb17dc64de43fe39d386a9041732959c3889eb
doc_id: 25551
cord_uid: lrdyzvxe

Severe acute respiratory syndrome coronavirus 2 or SARS-CoV-2 is a virus that belongs to the Coronaviridae family. This group of viruses commonly causes colds but possesses a tremendous pathogenic potential. In humans, an outbreak of SARS caused by the SARS-CoV virus was first reported in 2003, followed by 2012 when the Middle East respiratory syndrome coronavirus (MERS-CoV) led to an outbreak of Middle East respiratory syndrome (MERS). Moreover, COVID-19 represents a serious socioeconomic and global health problem that has already claimed more than four million lives. To date, there are only a handful of therapeutic options to combat this disease, and only a single direct-acting antiviral, the conditionally approved remdesivir. Since there is an urgent need for active drugs against SARS-CoV-2, the strategy of drug repurposing represents one of the fastest ways to achieve this goal. An in silico drug repurposing study using two methods was conducted. A structure-based virtual screening of the FDA-approved drug database on SARS-CoV-2 main protease was performed, and the 11 highest-scoring compounds with known 3CL(pro) activity were identified while the methodology was used to report further 11 potential and completely novel 3CL(pro) inhibitors. Then, inverse molecular docking was performed on the entire viral protein database as well as on the Coronaviridae family protein subset to examine the hit compounds in detail. Instead of target fishing, inverse docking fingerprints were generated for each hit compound as well as for the five most frequently reported and direct-acting repurposed drugs that served as controls. In this way, the target-hitting space was examined and compared and we can support the further biological evaluation of all 11 newly reported hits on SARS-CoV-2 3CL(pro) as well as recommend further in-depth studies on antihelminthic class member compounds. The authors acknowledge the general usefulness of this approach for a full-fledged inverse docking fingerprint screening in the future.

Severe acute respiratory syndrome coronavirus 2 or SARS-CoV-2 is a virus that belongs to the Coronaviridae family and is named after the crown serrations on its surface (Kahn, and McIntosh, 2005; Cui et al., 2019) . It is a single-stranded positive sense RNA (+ssRNA) virus (Gorbalenya et al., 2020; Zhu N. et al., 2020) . This group of viruses commonly causes colds but has tremendous pathogenic potential. In humans, an outbreak of SARS (severe acute respiratory syndrome) caused by the SARS-CoV virus was first reported in mainland China and Hong Kong in 2003, followed by 2012, when the Middle East respiratory syndrome coronavirus (MERS-CoV) led to an outbreak of Middle East respiratory syndrome (MERS) in Saudi Arabia, mainland China, United Arab Emirates, and the Republic of Korea (Hilgenfeld and Peiris, 2013; DeWit et al., 2016) . More recently, swine acute diarrhea syndrome coronavirus (SADS-CoV) causing severe acute porcine diarrhea syndrome has also been described with high porcine pathogenicity on top of a variety of documented coronaviruses in other animals (Yang et al., 2020; Lin et al., 2021) .

The emergence of the COVID-19 disease caused by the SARS-CoV-2 pathogen was reported in major media in December 2019 to have originated in Wuhan, Hubei, China , and spread worldwide in the first months of 2020, causing a pandemic of the COVID-19 disease (Li et al., 2020; Wang, et al., 2020) . COVID-19 is a serious socioeconomic and global health problem that has claimed more than 4,294,225 lives at the time of writing this article (Nicola et al., 2020) . Indeed, the majority of cases present with only mild symptoms, while a variable percentage (0.2%-5%) of patients progress to pneumonia and multiorgan failure, which can lead to death, especially without medical assistance at the secondary healthcare level (O'Driscoll et al., 2021; Malik et al., 2021) . The medical and academic communities, as well as the pharmaceutical industry, have responded immediately with intensive research campaigns aimed primarily at uncovering pathogenicity mechanisms, researching new drugs and developing vaccines, accompanied by new social guidelines and the dissemination of information and good hygiene practices by the relevant authorities (Fry et al., 2020; Meier et al., 2020) . Registered SARS-CoV-2 vaccines are available (Chen C. Z. et al., 2020; Amanat and Krammer, 2020) , and they represent the forefront in battle against COVID-19, but the high viral mutation rate, which can lead to structural changes in key viral proteins, may render available vaccines ineffective (Naqvi et al., 2020) . In late 2020, a novel SARS-CoV-2 alpha variant (B.1.1.7; Volz et al., 2021) and a beta variant (B.1.351; Tegally et al., 2020) were reported, followed by a gamma variant (P.1; Faria et al., 2021) and a new SARS-CoV-2 variant delta/delta+ in 2021 (B.1.617/AY.1), causing new infections and reinfections that are slowly spreading throughout the world (Moelling, 2021; Roy, et al., 2021) . We can respond by developing novel vaccines, but even with novel technologies such as mRNA, the response time is substantial (Badgujar et al., 2020; Verbeke et al., 2021) . Therefore, the development of other therapeutic options and novel drug approaches are essential for the future control of coronavirus infections (Kaddoura et al., 2020; Pooladanda et al., 2020; Sarkar et al., 2020) .

To date, there are only a handful of therapeutic options to combat this disease, with only one direct-acting antiviral, remdesivir, conditionally approved in Taiwan, followed by a rapid succession of conditional approvals in the EU and Canada. Following these conditional approvals, an emergency approval for remdesivir (a prodrug of GS-441524) was granted in the US and Japan in May 2020 (Lamb, 2020) . There is a tremendous research effort underway to develop novel drugs (Jin et al., 2020; Günther et al., 2021; Jukič et al., 2020) , but given the immediate need for active compounds against SARS-CoV-2, the strategy of drug repurposing represents one of the fastest options toward this goal (Dotolo et al., 2021; Singh et al., 2020; Gatti and De Ponti, 2021) . Most notably, the most commonly reported and direct-acting repurposed drugs include the antiviral agents favipiravir (Coomes and Haghbayan, 2020) , lopinavir (dynamic)-ritonavir (kinetic) (Ye et al., 2020) , ribavirin (Khalili et al., 2020) , interferons , the anthelmintic ivermectin (Schmith et al., 2020) , and the antimalarials chloroquine (Cortegiani et al., 2020) or hydroxychloroquine (Meo et al., 2020) , all shown in Figure 1 . Multiple reviews on this subject beyond the scope of this article are available to the reader (Saha et al., 2020; Sourimant et al., 2021) . Similar to remdesivir, favipiravir is a viral RdRp inhibitor, ribavirin inhibits IMPDH2, and lopinavir together with ivermectin inhibits viral 3CL pro . Chloroquine/ hydroxychloroquine is thought to modulate viral endosome maturation and interact with sigma receptors (Abate et al., 2020; . Other targeting approaches such as ACE2−RBD interaction have also been examined for drug repurposing (Hanson et al., 2020; Wei et al., 2020; de Oliveira et al., 2021) and compound sets evaluated on cell lines in vitro (Chen W. H. et al., 2020; Riva et al., 2020; Bakowski et al., 2021) . Especially on examination of sigma receptor ligands, a key observation was made where phospholipidosis was a shared mechanism underlying the antiviral activity of many repurposed drugs (hydroxychloroquine, azithromycin, amiodarone). Mehanistically, this disrupts lysosomal lipid catabolism and trafficking and results in an in vitro correlation between drug-induced phospholipidosis and antiviral activity disrupting the clear mechanism-based design decisions (Tummino et al., 2021) . This is especially evident in amphiphilic compounds and depends on the physicochemical properties (cLogP ≥ 3 and pKa ≥ 7.4) of drugs. Therefore, in this work, this was especially considered and compounds flagged in order to focus on molecules with therapeutic potential.

In the context of anti-coronavirus therapeutics-all repurposing approaches with a large body of conflicting data-we sought to conduct a transparent in silico drug repurposing study using known FDA-approved drugs on a well-described SARS-CoV-2 target 3CL pro or M pro (Zhu W. et al., 2020) . This target is a first choice for repurposing campaigns due to its extensive experimental support (Gordon et al., 2020) , available crystallographic data, and good biological evaluation data (Anand et al., 2003; Chiou et al., 2021; Osipiuk et al., 2021) . The protease is an attractive target as it plays a central role in the viral life cycle by processing the viral polyproteins pp1a and pp1ab at multiple distinct cleavage sites and complementary reports on repurposing research are available, further contextualizing the work herein (Kuzikov et al., 2021) . We Frontiers in Chemistry | www.frontiersin.org December 2021 | Volume 9 | Article 757826 proceeded to compute the inverse docking fingerprints to provide a focused outlook on a typical repurposing scenario and propose a consensus on the identified hit compounds. The work reveals a rarely studied in silico selectivity, and the authors have not overlooked the usefulness of this approach for future inverse docking fingerprint screening experiments to identify compounds that behave similarly across a large number of targets or explore the interactome (Sadegh, et al., 2020 ; Figure 2 ). The inverse docking procedure has already been used as a tool for drug repurposing before with positive results (Kharkar et al., 2014; Wang et al., 2019) . As an example, it revealed the potential new targets for tanshinone IIA used in the treatment of acute promyelocytic leukemia (Chen, 2014) . More recently, Ribone et al. (2021) applied inverse docking using multiple scoring functions for target proposal on SARS-CoV-2-repurposed drugs and discovered new potential targets for drugs with experimentally determined activity against SARS-CoV-2.

The compounds were obtained from the Drug Bank Database as a subset of 2,511 drugs in sdf format (Wishart et al., 2018) . The database was further expanded to 4,711 entries with calculation of tautomeric structures and ionization at pH 7.4 with further standard structure preparation steps such as enumeration of undefined chiral centers, removal of structural defects, and 3D structure minimization with optimization (using the OPLS3e force field) toward the final 3D conformation. For this work, the LigPrep tool from Schrödinger (Release Schrodinger 2020-4, FIGURE 1 | Commonly repurposed drugs against SARS-CoV-2 with proposed direct action (ritonavir is mainly a pharmacokinetic modifier for its partner in combination therapy).

FIGURE 2 | Virtual screening coupled to inverse docking protocol for drug repurposing. The first step is database selection; next is the VS campaign followed by a filtering step (filter off pains) with a final inverse docking fingerprint calculation to examine the target space where the compounds produce favorable binding poses (to this end, the ProBiS database was employed to conduct two experiments in parallel-one with all viral proteins and the other with focused Coronaviridae proteins). Hit selection was performed based on VS scores and prior available experimental data (ChEMBL) along with examination of inverse docking fingerprints.

Frontiers in Chemistry | www.frontiersin.org December 2021 | Volume 9 | Article 757826 Schrödinger, LLC, New York, NY, United States, 2020) was used. The exact parameters were as follows: ligprep -bff 16 -i 2 -ph 7.4 -pht 1.0 -s 8 -orig_file -orig_file_index 1 -isd input -osd output (Shelley et al., 2007; Greenwood et al., 2010) .

Ivermectin B1a/B1b and selamectin were modeled using the Avogadro chemical editor (Hanwell et al., 2012) and then optimized using Gaussian 16 (Frisch et al., 2016) in conjunction with the B3LYP method and the 6-31G(d) basis set, in the absence of a suitable 3D structure. The 3D structures of all other molecules used were obtained from the Drug Bank Database, ionized using LigPrep Ioniser software (Release Schrodinger 2020-4, Schrödinger, LLC, New York, NY, United States, 2020) at pH 7.4 ± 1 and their geometry optimized using the RDKit geometry optimization node in KNIME software.

We chose a well-described SARS-CoV-2 3CL pro complex with PDB ID: 6Y7M and a resolution of 1.9 Å .

, a peptide-like covalent inhibitor (MW 585.69 g/mol). As described previously (Jukič et al., 2021) , this complex comprises the peptidomimetic inhibitor OEW, which occupies all major pockets at the active site of the enzyme, leaving the S1 pocket accessible and the enzyme in the active conformation. After superposition with a reference structure (PDB ID:6LU7), the catalytic binding pocket was defined around Cys145 (Jin et al., 2020) . The covalent OEW bond was cleaved, the small molecule removed, and the Cys145 amino-acid residue regenerated (open-source PyMOL, version 2.1; DeLano, 2002). The target was prepared using the protein preparation module of Schrödinger Small-Molecule Discovery Suite (Release Schrödinger 2020-4, Schrödinger, LLC, New York, NY, United States, 2020). Missing hydrogen atoms were added, the H-bond network was optimized using the PROPKA tool at pH 7.4, waters were removed, and restrained minimization was performed 

In the virtual screening experiment, we performed molecular docking using CmDock (CmD) software (https://gitlab.com/Jukic/ cmdock/; Ruiz-Carmona et al., 2014) . The inputs were the FDAapproved drug database precalculated by LigPrep and the prepared receptor (cavity #1) as described in the previous section. First, we performed a redocking experiment in which we successfully redocked a regenerated OEW reference ligand (PDB ID: 6Y7M) and obtained the binding conformation of the crystal complex with a root mean square deviation (RMSD) of 1.34 Å. The CmD parameters were the standard docking protocol (dock.prm) with 100 runs, no constraints, and no score filters. Using the same exhaustive docking protocol, we performed the virtual screening experiment with the 4,711 FDA-approved drugs and analyzed the docking results using KNIME software (Fillbrunn et al., 2017) . The minimum docking score was −37.2, the maximum was 8.3, and the mean was -11.7 with a standard deviation of 5.8 after exhaustive docking with CmDock at the prepared receptor binding site (cavity #1).

We applied an inverse molecular docking approach to 11,640 viral protein structures, including 836 protein structures from the taxonomic lineage of Coronaviridae. Small molecule-binding sites were identified and prepared for inverse molecular docking using the ProBiS-Dock system (Depolli et al., 2013; Konc et al., 2021) . By reducing the size of the docking space and focusing on the binding sites, the time and complexity of inverse molecular docking are reduced. The creation of the ProBiS docking database, which served as a template for our viral database, is further described in Štular et al. (2016) and Konc et al. (2021) and has already been successfully used for mechanistic insights into the side effects of troglitazone and rosiglitazone (Kores et al., 2021) .

The inverse docking CANDOCK algorithm (Fine et al., 2020 ) applies a hierarchical approach to small-molecule reconstruction from the atomic lattice using generalized statistical potential functions and graph theory. The docking scores represent an approximation to the relative free energies of binding and have arbitrary units. The algorithm works in several consecutive steps. First, a small molecule is taken and broken into fragments. Then, the fragments are docked into protein-binding sites from the database using knowledge-based scoring methods. Then, the best-docked fragments are selected and linked using a fast maximum clique algorithm . In the course of the reconstruction, iterative dynamics is used for better placement of the ligand in the binding cavity. In a second step, the conformation optimization procedure is performed (Štular et al., 2016; Fine et al., 2020; Kores et al., 2021) . Validation of the algorithm has been extensively reported beforehand (Furlan et al., 2018; Kores et al., 2019; Fine et al., 2020; Kores et al., 2021) . To sum up the validation procedures, we FIGURE 3 | Inverse docking fingerprinting protocol and example of fingerprint comparison. Fingerprinting using heatmaps is useful for determining the similar binding patterns and find targets where compounds bind favorably. The darker the color in the fingerprint heatmaps, the less favorable the binding of the compound into target.

Frontiers in Chemistry | www.frontiersin.org December 2021 | Volume 9 | Article 757826 employed multiple methods. First is the redocking procedure, reported by Kores et al. (2019) and Kores et al. (2021) . In this procedure, the known structures from the Protein Data Bank (PDB) with co-crystallized ligands are taken, and the ligand redocking is preformed to show that the used docking algorithm can produce similar poses with the highest docking score to the native (co-crystallized) ones. This was done for resveratrol (Kores et al., 2019) and also for troglitazone and rosiglitazone (Kores et al., 2021) , where good agreement between predicted and experimentally determined poses was shown based on the RMSD of atomic positions. The second method combines the calculation of receiver operating characteristics (ROC), enrichment, and predictiveness curves (PC). The usage was reported by Furlan et al. (2018) , Fine et al. (2020) , and Kores et al. (2021) . Here the experimentally confirmed protein targets from the ChEMBL database for ligands were used to determine if the CANDOCK protocol produced similar binding targets. This analysis was done for curcumin (Furlan et al., 2018) and troglitazone and rosiglitazone (Kores et al., 2021) , where it showed that the CANDOCK protocol is expected to provide a good agreement with experiments. Top scoring hits identified by our methodology demonstrate also an experimental activity on 3CL pro (CHEMBL4495582, CHEMBL4495583). Therefore, our proposed protocol and the workflow are suitable for identification of novel potential actives on the studied target.

We used five reference compounds, namely, chloroquine and hydroxychloroquine, ivermectin B1a and B1b, and selamectin, which are commonly reused drugs as control compounds (Figure 1 ). In addition, the 11 compounds that scored highest in the virtual screen (Table 1) , all with previously reported activity on 3CL pro , and 11 compounds from our virtual screening experiment with the highest score that had not previously been reported to have activity on 3CL pro (CHEMBL4495582, CHEMBL4495583; Table 2 ) were examined. Using the CANDOCK inverse docking protocol, we elaborated their binding potential against two previously created databases of binding sites (viral protein target database-11,640 targets as well as 836 Coronaviridae protein targets) with a total of more than 325,000 individual docking experiments (Figure 3) . From the calculated conformations of all 27 compounds, we generated ranked lists of CANDOCK docking scores with all targets from the viral protein database or with targets from the Coronaviridae family of proteins ( Figure 3) . The fingerprint for a single molecule was then generated using the union of the 10 highest-scoring targets from all molecules in the study to obtain comparable fingerprints of equal length. The highestscoring targets were carefully examined for organisms and protein families. The lists of CANDOCK scores obtained in this way can be used as fingerprints for each compound, and the results are presented as heatmaps for analysis. The authors acknowledge the limitations of the inverse docking method in accurately identifying targets (yet the method is validated as referenced) but postulate that this approach can be used to compare a range of compounds and infer on their structural properties based on in silico interactions with a large number of prepared targets or even pharmacophore models. This simple approach can also pave the way for the development of further in silico selectivity methods (Figure 3) .

To identify accessible hit compounds with potentially favorable physicochemical properties and suitable downstream properties for biological evaluation, rigorous post-docking filtering was performed to screen out pan-assay interference compounds (PAINS; Shoichet, 2006; Baell and Holloway, 2010; Saubern et al., 2011) , aggregators (Irwin et al., 2015 ; to obtain compounds ready for biological evaluation in vitro), and structures with reactive functional groups (REOS; to prioritize toward non-covalent inhibitors; Walters et al., 1998; Zhu et al., 2013) . The KNIME software with RDKit nodes was applied to compare all structures in the library with the selection of SMARTS-formatted PAINS, aggregator, and REOS libraries and remove flagged matches. The 10 highest-scoring compounds were selected with the Z-score cutoff of −2.5, clustered, and examined in detail ( Table 1) .

The identified top-scoring repurposing candidates belong to nine distinct therapeutic classes according to ATC and are detailed in Table 1 , with the top three compounds belonging to a group of aminoglycoside antibacterials. Indeed, antibacterial compounds have been proposed as SARS-CoV-2-repurposing candidates, but we would like to highlight their value for the therapy of acquired COVID-19 bacterial coinfections rather than their role as direct-acting antiviral agents (Lai et al., 2020) . Moreover, their high scaffold decoration allows for additional target contacts in a typical docking experiment, and we urge the reader to be aware of this fact and interpret the results with this in mind (Meyer-Almes, 2020; Gyselinck et al., 2021) . We report that all compounds undergo non-covalent interactions and mainly occupy two different binding poses with classical P1-P2 pocket occupation ( Figure 4B ; dibekacin, micronomicin, darolutamide, propafenone) or P1′-P2 pocket occupation ( Figure 4C) , exemplified by pexidartinib, canagliflozin, nebivolol, and filgotinib. The first compound, amikacin, is slightly larger with a MW of 585.6 g/mol and occupies all three P1′-P1-P2 pockets of the active site of 3CL pro . The predicted bound conformations for the first 10 hit compounds are analogous with key contacts Thr25, Leu27, Gly143, Ser144, Cys145, His163, His164, Met165, Glu166, Asp187, Thr190, Gln189, and Gln192 at the active site of 3CL pro (Figure 4) . Our top-scoring compounds have also been previously reported and biologically evaluated against 3CL pro . Results of extensive screening campaign can also be observed in the ChEMBL database under the comprehensive assay (SARS-CoV-2 3CL-Pro protease inhibition percentage at 20 µM by a FRET kind of response from peptide substrate) with more than 8,700 data points at the time of writing. We report these compounds as 3CL pro hit identification control and support their repurposing research via further in silico inverse docking fingerprint analysis. Nevertheless, we are compelled to report further 11 potential 3CL pro inhibitors (compounds 12-22) identified by our virtual screening experiment without any existing 3CL pro activity data (CHEMBL4495582, CHEMBL4495583) that can be of use to the SARS-CoV-2 repurposing research ( Table 2) .

New 11 reported hit compounds (12-22) belong to eight distinct therapeutic classes according to ATC with two compounds (15, 21) not yet classified as being experimental agents. Examining the ChEMBL database, no compound possesses activity on coronavirus targets as of yet. In this hit list, we also do not report antibacterials, as they are not favorable for drug repurposing causing additional selection pressure and antibacterial resistance problems (Andersson et al., 2016) . The list represents small molecules suitable for further biological evaluation on SARS-CoV-2 3CL pro without phospholipidosis potential as identified by Tummino et al. (2021) . Majority of compounds occupy the P1-P2 pocket at the 3CL pro active site near Cys145 ( Figure 5A ) analogous to the PDB ID: 6Y7M OEW FIGURE 6 | Heatmap representation of compound fingerprints for the complete viral target database (11,640 proteins) of all hit compounds. The total number of combined targets is 144, and the list of PDB IDs is found in Supplementary Table S20 . The values shown in the heatmap were calculated and colored according to the normalized docking score for each compound. Interval 0 means that the compound did not interact with the target, while interval 5 means that the compound had a most favorable docking score. Protein targets are grouped according to their class and classes emphasized in blue color. reference ligand. Highest-ranking compound 12 (olodaterol) thus makes hydrophobic contacts with Met165 and Glu166; hydrogen bonds with Gly143, Ser144, Cys145, Glu166, and Gln192; and cation-π interactions toward His41 ( Figure 5 ; additional details in Supplementary Material). Moody et al. also conducted a virtual screening experiment on 3CL pro and reported a list of 56 top scoring candidates on 3CL pro , selected according to the highest S-score (between −9.95 and −4.24). After biological evaluation, Moody et al. proposed six repurposing candidates with IC 50 values ranging from 21.5 to 75.5 µM, namely, micafungin (4th; −9.60 S-score), an antifungal agent of the echinocandin class, ombitasvir (12th; −8.97 S-score), an HCV NS5A inhibitor, boceprevir (23rd; −8.42 S-score), a representative of an HCV protease inhibitor, ivermectin (32nd; −7.74), an antiparasitic that binds to glutamate-gated chloride channels found in invertebrate nerve and muscle cells, tipranavir (35th; −7.48 S-score), an HIV protease inhibitor, and paritaprevir (36th; −7.43 S-score), an HCV NS3-4A serine protease inhibitor (Mody et al., 2021) . The observed differences in the hit list can be attributed to the screening software. Moody et al. used the MOE software suite with a different approach to scoring (S-score calculated using the London dG score for placement and the GBVI/WSA dG score for pose refinement). To illustrate the difference, micafungin, an antifungal drug with a molecular mass of 1,270.28 g/mol, was not included, while ombitasvir, boceprevir, ivermectin, tipranavir, and paritaprevir were scored by respectively. However, all 

To identify the protein targets to which our identified hit compounds express the highest binding potential, we performed rigorous post-docking filtering and expressed only top-scoring targets for reader benefit. We recorded the lists of proteins for each compound and considered only the highestscoring targets ( Table 3) . Complete target protein lists are found in Supplementary Tables S1-S3. To generate inverse docking target interaction fingerprints, we combined the 10 highestscoring viral protein targets of each compound into one list . We removed duplicate proteins and included docking scores for all targets on the list for each compound. A target interaction space was then plotted as a heatmap as shown in Figure 6 . The same procedure was used for the Coronaviridae protein subset experiment (Figure 7) . Complete lists of successfully docked Coronaviridae family targets for each compound are found in Supplementary Tables S4-S19.

An examination of our inverse docking fingerprints reveals that they are unique to each compound, suggesting that subtle differences in compound conformational space and scaffold decoration (chloroquine and hydroxychloroquine, ivermectin B1a and B1b) have a profound effect on the scope of the target reach, making them very useful for the future development of models (Belyaeva et al., 2021; Kumar Das FIGURE 7 | Heatmap representation of compound fingerprints for the Coronaviridae database subset (836 proteins) for all compounds. The total number of combined targets is 96, and the list of PDB IDs is found in Supplementary Table S21 . The values shown in the heatmap were calculated and colored according to the normalized docking score for each compound. Interval 0 means that the compound did not interact with the target, while interval 5 means that the compound had a most favorable docking score. Protein targets are grouped according to their class and classes emphasized in blue color. Fingerprint profile similarities are colored green. Two "repurpose" subsets represent two different fingerprint profiles within the repurpose compounds group.

Frontiers in Chemistry | www.frontiersin.org December 2021 | Volume 9 | Article 757826 et al., 2021) and machine learning (D'Souza et al., 2020) . Namely, the compound's ability to conform to a particular set of protein targets is used as ligand structural information that can be of use also when comparing a set of diverse compounds (e.g., can two compounds, even structurally dissimilar conform to a larger set of protein targets and produce favorable binding modes?) The most studied target of SARS-CoV-2 is the 3CL pro , and it is actually postulated as a target (Mody et al., 2021) for the previously reported repurposed drug ivermectin (Kaur et al., 2021; Kern et al., 2021; Nardelli et al., 2021) . As is shown in Table 3 , the major targets of ivermectin B1a and B1b, as well as the structurally similar selamectin, were identified as proteases. We can support previous reports of ivermectin targeting (Eweas et al., 2021) , while with our approach we are able to also place the compounds in the context of other potential therapeutic targets (Zaidi and Dehgani-Mobaraki, 2021 ; Figure 6 ). The fingerprint profiles of ivermectins and selamectin are also similar ( Figure 6 ). In comparison, the targets of chloroquine and hydroxychloroquine, calculated by inverse docking, are not proteases and their fingerprints differ significantly. Following the initial reports (Garcia-Cremades et al., 2020) on their efficacy and viral targeting (Adeoye et al., 2020) , we are unable to report similar observations and we can treat these compounds (and their fingerprint profile)as negative control examples, as recently reported (Shah, 2021) . The fingerprints described can thus be of use in an extensive inverse docking fingerprint screening of a large database of compounds to identify compounds with a similar fingerprint profile.

Upon inspection of the inverse docking fingerprints and top docking poses for all hit compounds 1-11 from the first virtual screening experiment with FDA-approved drugs, all drugs except filgotinib have high docking potential against proteases (Table 3) . Beforehand, Ribone et al. (2021) identified protease (PLpro) as the main target of hydroxychloroquine, while further suggesting a human protein PIKfyve as a main target of pexidartinib. Therefore, we can support the potential of the identified FDAapproved drugs to inhibit SARS-CoV-2 3CL pro and also treat the compounds as controls (experimental 3CL pro activity; CHEMBL4495582, CHEMBL4495583). For example, we can postulate that the diverse set of compounds can produce favorable binding poses at the active site of HIV proteases so this set of compounds can access the conformational space that is similar or presents a similar set of transient pharmacophoric elements. This identified potential (similarity in accessing other targets) of a set of studied compounds can then be leveraged in further experimental and repurposing experiments to access novel chemical space.

We fingerprinted the compounds 1-22 using the Coronaviridae family subgroup in a similar manner. The proteins of compounds 1-11 controls (experimental 3CL pro activity) are used for fingerprint comparison with novel repurposing candidates without prior experimental information 12-22 (Figure 7) . The highest-scoring Coronaviridae targets belong to the protease family (Supplementary  Tables S4-S19) , making all newly reported compounds except arzoxifene, a potential SARS-CoV-2 3CL pro inhibitor that should be evaluated further (Figure 7) .

If we compare the fingerprint of propafenone to the other repurposing candidates, we can see that it has significantly more unfavorable targets than other compounds (Figure 7) . We also observed that propafenone possesses a distinct fingerprint profile in comparison to other studied drugs. From this, one can postulate that propafenone could possess different mechanisms of action to the other compounds. Each fingerprint is unique; nevertheless, global trends emerge when examining multiple compounds in parallel (Figure 7) . Namely, pexidartinib and arzoxifene show similar fingerprint profiles (Figure 7 ; bottom) which indicates less favorable binding to majority of targets, and both are incidentally also flagged as CAD compounds with phospholipidosis potential (Tables 2, 3) . This information can be leveraged in further full-scale inverse docking screening, as stated beforehand.

To further elaborate on inverse docking fingerprints, two case studies were conducted. First is a case study of a fingerprinting target, papain-like protease (PL pro ). This target was selected as a random representative of the most abundant protease class. Case compounds were also randomly selected, one from each fingerprint-like group: dibekacin, hydroxychloroquine, olodaterol, pexidartinib, and udenafil. As detailed in Supplementary Figure S1 , all five compounds bind into the same binding pocket, validating the target database (DeLano, 2002 , Adasme et al., 2021 Pettersen et al., 2004) . More detailed analysis of the binding interactions shows that udenafil has hydrophobic interactions with Asp165 and Tyr269; hydrogen bonds with Leu163, Tyr265, Tyr269, and Tyr274; and salt bridges to Asp165 and Asp303, suggesting that it may have a more favorable binding potential as a repurposing candidate compared to pexidartinib, which shows hydrophobic interactions with Leu163, Gln270, and π-π stacking with Tyr269. This observation is also immediately apparent from the fingerprint profile in Figure 7 . Second, a case study of the fingerprint compound olodaterol is presented. This compound was chosen because it is the highest-scoring repurposing candidate for which data on 3CL pro activity are not yet available. We investigated the binding positions of the repurposing candidate to different protein targets included in its inverse docking fingerprint. The representatives of the target proteins were randomly selected from each protein target class: 3C-like protease and papain-like protease, NSP16 transferase, and spike protein. A detailed analysis of the binding interactions (Supplementary Material) shows that the repurposing candidate has the best docking results and the most favorable binding conformations toward proteases compared to the other targets (3CL pro : hydrogen bonds with Leu141, Gly143, Ser144, Cys145, and Glu166; PL pro : hydrophobic interactions with Asp165, Tyr265, and Tyr269; and hydrogen bonds with Asp165, Arg167, Glu168, Tyr269, and Gln192). The observations thus support our findings and suggestions on the new SARS-CoV-2 repurposing candidates.

We conducted a thorough virtual screening experiment on SARS-CoV-2 3CL pro using CmDock software and a database of FDAapproved drugs and identified the highest-scoring drug repurposing candidates. All newly reported candidates (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) are readily available and show favorable non-covalent interactions at the active site of 3CL pro , and all newly identified hit compounds show a low propensity for phospholipidosis, with the exception of arzoxifene. The latter compound belongs to a typical cathionic amphiphilic drug scaffold but has not been identified as a known inducer of phospholipidosis. Furthermore, in reviewing the inverse docking fingerprints, we found that the majority of the identified FDA-approved repurposing candidates have favorable docking scores against Coronaviridae family proteases and viral proteases in general. In addition, we support current in silico studies on 11 top-scoring compounds (1-11) as well as on antihelminthic class member compounds. We postulate the application of this approach to future inverse docking fingerprint screening experiments to investigate the selectivity of compound interaction in silico and to identify similarly interacting compounds in large protein databases.

The original contributions presented in the study are included in the article/Supplementary Material; further inquiries can be directed to the corresponding authors.

MJ and KK conceived and designed the experiments. MJ and KK performed the experiments. MJ, KK, DJ, and UB analyzed the data. All co-authors wrote the paper. All authors have given approval to the final version of the manuscript.

This work was supported by the Slovenian Ministry of Science and Education infrastructure project grants HPC-RIVR and RI-SI-ELIXIR and by the Slovenian Research Agency (ARRS) program and project grants P2-0046, J1-2471, J1-1715, N1-0209, and J1-9186 as well as by the Slovenian Ministry of Education, Science and Sports program grant OP20.04342.

PB28, the Sigma-1 and Sigma-2 Receptors Modulator With Potent Anti-SARS-CoV-2 Activity: A Review About its Pharmacological Properties and Structure Affinity Relationships

PLIP 2021: Expanding the Scope of the Protein-Ligand Interaction Profiler to DNA and RNA

Repurposing of Chloroquine and Some Clinically Approved Antiviral Drugs as Effective Therapeutics to Prevent Cellular Entry and Replication of Coronavirus

SARS-CoV-2 Vaccines: Status Report

Pro ) Structure: Basis for Design of Anti-SARS Drugs

Mechanisms and Consequences of Bacterial Resistance to Antimicrobial Peptides

Vaccine Development Against Coronavirus (2003 to Present): An Overview, Recent Advances, Current Scenario, Opportunities and Challenges

New Substructure Filters for Removal of pan Assay Interference Compounds (PAINS) From Screening Libraries and for Their Exclusion in Bioassays

Drug Repurposing Screens Identify Chemical Entities for the Development of COVID-19 Interventions

Causal Network Models of SARS-CoV-2 Expression and Aging to Identify Candidates for Drug Repurposing

Identifying SARS-CoV-2 Entry Inhibitors Through Drug Repurposing Screens of SARS-S and MERS-S Pseudotyped Particles

The SARS-CoV-2 Vaccine Pipeline: An Overview

A Potential Target of Tanshinone IIA for Acute Promyelocytic Leukemia Revealed by Inverse Docking and Drug Repurposing

Repurposing Existing Drugs: Identification of SARS-CoV-2 3C-Like Protease Inhibitors

Favipiravir, an Antiviral for COVID-19?

A Systematic Review on the Efficacy and Safety of Chloroquine for the Treatment of COVID-19

Origin and Evolution of Pathogenic Coronaviruses

Frontiers in Chemistry | www.frontiersin.org

Repurposing Approved Drugs as Inhibitors of SARS-CoV-2 S-Protein from Molecular Modeling and Virtual Screening

Brief Review on Repurposed Drugs and Vaccines for Possible Treatment of COVID-19

SARS and MERS: Recent Insights into Emerging Coronaviruses

Pymol: An Open-Source Molecular Graphics Tool

Exact Parallel Maximum Clique Algorithm for General and Protein Graphs

A Review on Drug Repurposing Applicable to COVID-19

Machine Learning Models for Drug-Target Interactions: Current Knowledge and Future Directions

Molecular Docking Reveals Ivermectin and Remdesivir as Potential Repurposed Drugs against SARS-CoV-2

Genomic Characterisation of an Emergent SARS-CoV-2 Lineage in Manaus: Preliminary Findings

KNIME for Reproducible Cross-Domain Analysis of Life Science Data

CANDOCK: Chemical Atomic Network-Based Hierarchical Flexible Docking Algorithm Using Generalized Statistical Potentials

Gaussian 16 Rev. A.03

Inverse Molecular Docking as a Novel Approach to Study Anticarcinogenic and Anti-Neuroinflammatory Effects of Curcumin

Optimizing Hydroxychloroquine Dosing for Patients With COVID-19: An Integrative Modeling Approach for Effective Drug Repurposing

Drug Repurposing in the COVID-19 Era: Insights From Case Studies Showing Pharmaceutical Peculiarities

The Species Severe Acute Respiratory Syndrome-Related Coronavirus: Classifying 2019-nCoV and Naming it SARS-CoV-2

Towards the Comprehensive, Rapid, and Accurate Prediction of the Favorable Tautomeric States of Drug-Like Molecules in Aqueous Solution

X-ray Screening Identifies Active Site and Allosteric Inhibitors of SARS-CoV-2 Main Protease

Rationale for Azithromycin in COVID-19: an Overview of Existing Evidence

Targeting ACE2-RBD Interaction as a Platform for COVID-19 Therapeutics: Development and Drug-Repurposing Screen of an AlphaLISA Proximity Assay

Avogadro: An Advanced Semantic Chemical Editor, Visualization, and Analysis Platform

From SARS to MERS: 10 Years of Research on Highly Pathogenic Human Coronaviruses

An Aggregation Advisor for Ligand Discovery

Structure of Mpro from SARS-CoV-2 and Discovery of its Inhibitors

Prioritisation of Compounds for 3CLpro Inhibitor Development on SARS-CoV-2 Variants

Ensemble Docking Coupled to Linear Interaction Energy Calculations for Identification of Coronavirus Main Protease (3CLpro) Non-Covalent Small-Molecule Inhibitors

COVID-19 Therapeutic Options under Investigation

History and Recent Advances in Coronavirus Discovery

Ivermectin as a Potential Drug for Treatment of COVID-19: An In-Sync Review With Clinical and Computational Attributes

Modeling of SARS-CoV-2 Treatment Effects for Informed Drug Repurposing

Novel Coronavirus Treatment With Ribavirin: Groundwork for an Evaluation Concerning COVID-19

Reverse Docking: a Powerful Tool for Drug Repositioning and Drug rescue

ProBiS-Dock Database: A Web Server and Interactive Web Repository of Small Ligand−Protein Binding Sites for Drug Design

Mechanistic Insights Into Side Effects of Troglitazone and Rosiglitazone Using a Novel Inverse Molecular Docking Protocol

Discovery of Novel Potential Human Targets of Resveratrol by Inverse Molecular Docking

Data Science in Unveiling COVID-19 Pathogenesis and Diagnosis: Evolutionary Origin to Drug Repurposing

Reprofiling of Approved Drugs against SARS-CoV-2 Main Protease: An In-Silico Study

Identification of Inhibitors of SARS-CoV-2 3CL-Pro Enzymatic Frontiers in Chemistry | www

Activity Using a Small Molecule In Vitro Repurposing Screen

Co-Infections Among Patients With COVID-19: The Need for Combination Therapy With Non-Anti-SARS-CoV-2 Agents?

Remdesivir: First Approval

Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia

Animal Coronavirus Diseases: Parallels with COVID-19 in Humans

Biomarkers and Outcomes of COVID-19 Hospitalisations: Systematic Review and Meta-Analysis

Public Perspectives on Protective Measures during the COVID-19 Pandemic in the Netherlands, Germany and Italy: A Survey Study

Efficacy of Chloroquine and Hydroxychloroquine in the Treatment of COVID-19

Repurposing Approved Drugs as Potential Inhibitors of 3CL-Protease of SARS-CoV-2: Virtual Screening and Structure Based Drug Design

Identification of 3-chymotrypsin like Protease (3CLPro) Inhibitors as Potential Anti-SARS-CoV-2 Agents

Within-Host and Between-Host Evolution in SARS-CoV-2-New Variant's Source

Validation of an Empirical RNA-Ligand Scoring Function for Fast Flexible Docking Using RiboDock ®

Insights Into SARS-CoV-2 Genome, Structure, Evolution, Pathogenesis and Therapies: Structural Genomics Approach

Basis Dis. 1866

Crying Wolf in Time of Corona: The Strange Case of Ivermectin and Hydroxychloroquine. Is the Fear of Failure Withholding Potential Life-Saving Treatment from Clinical Use? Signa Vitae

The Socio-Economic Implications of the Coronavirus Pandemic (COVID-19): A Review

Age-specific Mortality and Immunity Patterns of SARS-CoV-2

Structure of Papain-Like Protease From SARS-CoV-2 and its Complexes With Non-Covalent Inhibitors

UCSF Chimera?A Visualization System for Exploratory Research and Analysis

The Current Understanding and Potential Therapeutic Options to Combat COVID-19

Target Identification for Repurposed Drugs Active against SARS-CoV-2 via High-Throughput Inverse Docking

Discovery of SARS-CoV-2 Antiviral Drugs Through Large-Scale Compound Repurposing

Global Variants of COVID-19: Current Understanding

rDock: A Fast, Versatile and Open Source Program for Docking Ligands to Proteins and Nucleic Acids

Exploring the SARS-CoV-2 Virus-Host-Drug Interactome for Drug Repurposing

Repurposing Drugs, Ongoing Vaccine, and New Therapeutic Development Initiatives against COVID-19

Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives

KNIME Workflow to Assess PAINS Filters in SMARTS Format. Comparison of RDKit and Indigo Cheminformatics Libraries

The Approved Dose of Ivermectin Alone Is Not the Ideal Dose for the Treatment of COVID-19

Chloroquine and Hydroxychloroquine for COVID-19: Perspectives on Their Failure in Repurposing

Epik: a Software Program for pK a Prediction and Protonation State Generation for Drug-like Molecules

Interpreting Steep Dose-Response Curves in Early Inhibitor Discovery

Drug Repurposing Approach to Fight COVID-19

Progress and Pitfalls of a Year of Drug Repurposing Screens against COVID-19

Discovery of Mycobacterium Tuberculosis InhA Inhibitors by Binding Sites Comparison and Ligands Prediction

Emergence and Rapid Spread of a New Severe Acute Respiratory Syndrome-Related Coronavirus 2 (SARS-CoV-2) Lineage with Multiple Spike Mutations in South Africa

Drug-induced Phospholipidosis Confounds Drug Repurposing for SARS-CoV-2

The Dawn of mRNA Vaccines: The COVID-19 Case

Transmission of SARS-CoV-2 Lineage B. 1.1. 7 in England: Insights From Linking Epidemiological and Genetic Data

Virtual Screening-An Overview

A Novel Coronavirus Outbreak of Global Health Concern. The lancet

Frontiers in Chemistry | www.frontiersin.org

ACID: a Free Tool for Drug Repurposing Using Consensus Inverse Docking Strategy

In Silico Screening of Potential Spike Glycoprotein Inhibitors of SARS-CoV-2 with Drug Repurposing Strategy

DrugBank 5.0: a Major Update to the DrugBank Database

A New Coronavirus Associated With Human Respiratory Disease in China

Swine Enteric Alphacoronavirus (Swine Acute Diarrhea Syndrome Coronavirus): An Update Three Years after its Discovery

Clinical Efficacy of Lopinavir/Ritonavir in the Treatment of Coronavirus Disease 2019

The Mechanisms of Action of Ivermectin Against SARS-CoV-2: An Evidence-Based Clinical Review Article

Crystal Structure of SARS-CoV-2 Main Protease Provides a Basis for Design of Improved α-ketoamide Inhibitors

Interferon-α2b Treatment for COVID-19

A Novel Coronavirus From Patients With Pneumonia in China

Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-Throughput Screening

Hit Identification and Optimization in Virtual Screening: Practical Recommendations Based on a Critical Literature Analysis

We gratefully acknowledge the support of NVIDIA Corporation with the donation of GPU hardware that was used in this research. We also thank Rita Podzuna, Director at Schrödinger, for her help. We especially thank OpenEye software for their support in our research.

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fchem.2021.757826/ full#supplementary-material Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.